Background. Seasonal outbreaks of dengue often result in hundreds of dengue-suspected cases where a clinical diagnosis cannot be confirmed. Usually, during large outbreaks of dengue and other pathogens that can cause acute febrile illnesses, the search for secondary pathogens with similar disease outcomes is rare.
(DENV) outbreak in Guarujá, a touristic city embedded in Brazil's South Atlantic rainforest and disposed to seasonal dengue outbreaks [22] [23] [24] . Guarujá is adjacent to Santos, the largest seaport in Brazil with intense daily commuting with the city of São Paulo, the largest conurbation in South America. We found that 63.2% of patients were viremic for B19V and many had clinical outcomes indistinguishable to dengue fever. It was previously unknown that B19V was compromising dengue diagnostics and our findings provide a warning that there may be other, more severe pathogens that could be missed if passive surveillance systems remain as they are.
MATERIALS AND METHODS

Sample Collection
Samples were collected from 10 November 2013 to 25 February 2014. We collected 182 serum samples from patients who showed signs of acute febrile illness, but tested negative for all DENV-specific enzyme-linked immunosorbent assay (ELISA) and polymerase chain reaction (PCR) assays. Patients of any age with symptoms and clinical signs of dengue disease were examined in primary health or emergency care units. Patients were included who presented with the following symptoms and complications: fever, joint pain (arthralgia), headache, rash, retro-orbital pain, muscle pain (myalgia), difficulty swallowing (odynophagia), vomiting, diarrhea, and thrombocytopenia.
Molecular Diagnostic Assays for B19V
Samples were extracted on the NUCLISENS easyMag platform (bioMérieux). The eluate, containing RNA and total DNA, was stored in a freezer at -70°C until the time of its use. PCR, followed by a seminested reaction, was performed targeting the viral protein (VP) 1/VP2 region using primers designed by Durigon et al and Erdman et al [25, 26] . The extracted nucleic acids were also submitted to a quantitative real-time PCR assay utilizing the LightMix Kit Parvovirus B19 EC (TIB MOLBIOL GmbH, Berlin, Germany), High Pure PCR Template Preparation, and the Cobas z 480 Analyzer (Roche Molecular Diagnostics Pleasanton, California). The standard curve was prepared from target DNA provided in 6 different quantities to yield from 10 1 to 10 6 target molecules in 5 µL once resolved. The kit provided a system to quantitate B19V genotypes 1-3 in a nucleic acid extract and a control reaction to monitor extraction and eventual PCR inhibition. Positive control and "no template control" were included in each run. The amount of virus per sample (viral load) was reported in viral genome copies (vgc)/ mL. Primers, PCR conditions, and reagents are described in detail in the Supplementary Materials.
B19V Serological Assays
All serum samples were tested for immunoglobulin M (IgM)-class and immunoglobulin G (IgG)-class antibodies against B19V using quantitative enzyme immunoassays (SERION ELISA classic Parvovirus B19 IgG/IgM/IgA; Institut Virion/ Serion, Würzburg, Germany). Samples were considered to have IgM or IgG seroprevalence if they were greater than or equal to their established cutoffs, which were obtained by following the manufacturer's instructions and generated controls. For IgM, samples with <10 U/mL were considered negative, between 10 and 15 U/mL borderline, and >15 U/mL seropositive. For IgG, samples with <2 U/mL were considered negative, between 2 and 5 U/mL borderline, and >5 U/mL seropositive.
Sanger Sequencing
Samples that were found positive for B19V using a seminested PCR were selected for downstream sequencing. Primers, PCR conditions, and reagents are described in detail in the Supplementary Materials. Sequences were submitted to GenBank and can be found under the accession numbers MG765329-MG765371.
Patient Medical Records
Patient records were retrospectively collected with the kind aid of the Guarujá Secretary of Health. From the 182 total serum samples collected, only 111 records that included basic patient information were available. Only 70 contained diagnostic information and 56 contained a physician's medical records from all Guarujá public healthcare clinics. Only 25 had usable hematology data. All adult subjects included in this study provided informed written consent, and a parent or guardian of any child participant provided the written informed consent on their behalf.
Phylogenic Analysis
To infer the phylogenetic relationships of our B19V sequences with other partial VP1/VP2 genome sequences from GenBank, sequences were aligned using Clustal Omega version 1.2.1 (http://www.clustal.org/omega) and manually curated by using JalView version 1.18-B8 (http://www.jalview.org/download). A maximum-likelihood tree was exhaustively estimated in the nucleotide general time-reversible with γ-distribution rate variation and invariant sites model. Support for the tree was accessed after 10 000 nonparametric bootstrap replicates with FastTree version 2.1.8 [27] .
RESULTS
RNA Sequencing of Pooled Serum Samples
From November 2013 to February 2014 during a dengue outbreak, 182 serum samples were collected from patients who visited the city's public health clinics with symptoms of an acute febrile illness, with some (34.2%) diagnosed with dengue fever, but many were undiagnosed. We found that in all these cases, there was no evidence for DENV infection or any other nationally prevalent arboviruses such as Zika virus, Chikungunya virus, Mayaro virus, or yellow fever virus. From here, samples were grouped into 24 pools and were subjected to total RNA sequencing to screen for other viruses with a similar disease outcome to dengue. Using reads from individual pools, we were able to de novo assemble a complete or nearly complete B19V genome from 10 of the 24 pools (Supplementary Figure 1) . Albeit at a lower frequency, we also found sequences from GB virus C, hepatitis C virus, hepatitis A virus, and many different groups of phages and retroviruses (Supplementary Materials).
PCR Amplification of B19V
Once we identified B19V, we designed specific primers for the VP1/VP2 region of B19V. Of the 182 patients, 115 (63.2%) were PCR positive for B19V using a seminested reaction ( Table 1) . The median age of these patients was 27. In fact, nearly 60% of the patients were between 18 and 39 years of age.
From the patients where DNA was amplified by PCR, 8 were also positive for the B19V IgM antibody. Only 4 samples were PCR negative and IgM positive. A total of 50 patients (27.5%) with B19V DNA were negative for both B19V IgM and IgG, suggesting a first-time exposure. Additionally, 47 (25.8%) patients were PCR positive, IgM negative, and IgG positive, which is a serological profile that has been associated with a prior, persistent, or reoccurring infection [28] [29] [30] [31] . Only 23 patients (12.6%) were negative for all 3 diagnostic assays for B19V.
To determine whether B19V infections were acute or recent (reoccurring or persistent) in PCR positive, IgM negative, and IgG positive samples, we analyzed the quantity of viral genome copies/mL of B19V DNA in 89 samples using quantitative realtime reverse-transcription PCR (qRT-PCR) ( Table 2 ). B19V was quantified in 80 (89.8%) of the tested samples, with 5 above the upper limit of quantification (10 6 vgc/mL). A threshold of 10 4 vgc/mL has been suggested to determine whether an infection is acute (≥10 4 vgc/mL) or persistent (<10 4 vgc/mL) infection [32] . We found no significant differences in B19V DNA quantity between the acute qRT-PCR-positive/IgG-positive samples and the acute qRT-PCR-positive/IgG-negative samples, nor when we compared past infections. As contaminations have been reported as a problem for B19V diagnostics, we took precautions to ensure the reliability of our results. For each sample, PCR assays were performed in duplicate and on separate days to avoid false-positive DNA amplifications. Prior to and upon completion of both assays, we sterilized all materials and used new reagents as well as PCRspecific negative controls for each PCR run and associated gel. We also tested 35 serological samples of febrile patients from another Brazilian state, Sergipe, that were suspected of chikungunya virus [33] , but were found negative for both B19V PCR and IgM antibodies.
We then retrieved the patient's date of attendance at a public clinic from 111 of the 115 patients positive for B19V DNA. Cases ranged from 4 November 2013 to 25 February 2014. We mapped the B19V-positive patient's date of attendance by week to discover whether was the time where case incidence was highest ( Figure 1A ). Peak incidence occurred during the week of 10 November 2013. We also obtained the addresses for 68 of the PCR-positive patients and mapped the distribution of cases around the city ( Figure 1C ). We found that the majority of cases were in the Santo Antônio district where the main administrative, mass transportation, and commercial facilities are located. Highly populated districts as Morrinhos (6 cases), Enseada (7 cases), and Vila Zilda (7 cases) also had a large proportion of localized cases.
Clinical Presentations of B19V-positive Patients
For 70 patients, we were able to retrieve a more detailed medical record with a range of incomplete information including symptoms, hematology, complications, diagnoses, and drug Nine samples were negative (0 vgc/mL).
recommendations. Several medical records were discarded because they were either lacking data or were completely illegible. However, all patients included in our study presented 1 or more dengue-like symptom(s), but not all medical records included patients' symptoms during their attendance (see Table 1 footnote). Nevertheless, we annotated the symptoms and complications presented from 56 patients who were also viremic for B19V during their clinical attendance (Tables 3 and 4) . Fever (70%), myalgia (61%), and headaches (43%) were the most prevalent clinical presentations in patients. Only 12 of these patients (21%) had presentations of arthralgia (6 patients) or rash (6 patients).
Eight patients (14.3%) described retro-orbital pain at their attendance, a symptom that, to the best of our knowledge, has no current association with acute or persistent B19V infection. We also obtained data from patients with complications such as vomiting and diarrhea. Additionally, 25 medical records included patient platelet count information that helped us determine the prevalence of thrombocytopenia (platelets <150 000 cells/μL) in viremic patients. In total, 15 patients (60%) presented with thrombocytopenia during their clinical attendance.
Because people can be persistently infected by B19V, the sole existence of B19V DNA in a patient's serum can be misleading for a clinical diagnosis of an acute infection without any supporting clinical information, especially if paired sampling or a quantitative PCR or ELISA analysis was not done [34, 35] . The presence of the B19V IgM antibody is a strong indicator of an acute infection [36, 37] . Therefore, we looked to see if these patients presented different symptoms in relation to their serological profile (Table 3) negative and IgG positive, which could indicate a persistent or reoccurring infection [36, 38, 39] . The other 24 patients (with medical records) were negative for both antibodies, suggesting a first-time and recent infection. Given that 50.4% of our PCR positive-only or PCR/IgM-positive patients appeared to be acutely infected, it is fair to assume that we sampled from an ongoing B19V outbreak. We did not find any significant differences between serological profiles and clinical presentations.
Next we compared clinical presentations by the age and sex of the patient (Table 4) . We grouped patients by those who were 5-17 years of age (children) and those who were ≥18 years (adults) at the time of their attendance. Notably, we found that the prevalence of myalgia was significantly higher in adult patients compared to younger patients (Fisher exact test, P = .02). Likewise, we also observed that only adults presented with symptoms of arthralgia, odynophagia (difficulty swallowing), and diarrhea. In disagreement to some previous works [40, 41] , we did not see any significant differences in symptoms between men and women. However, we did find that only men reported having diarrhea at their clinical attendance (Fisher exact test, P = .02).
Phylogeny of B19V
To explore the genetic diversity of B19V in Guarujá, we amplified a small region (sequences ranged from 427 to 560 nucleotides in length) of the VP1/VP2 gene that has been used for genotyping in other works [42, 43] . We then aligned our sequences (GenBank accession numbers MG765329-MG765371) with all publicly available B19V sequences with the country of isolation and collection date available from GenBank. Our phylogenetic estimation showed that our sequences (orange tips) are most similar to the B19V genotype 1 sequences (Figure 2 ). It is possible that there was >1 emergence of B19V in Guarujá. Our sequences were genetically similar to 2 sequenced isolates from the city of São Paulo: 1 from 2010 (GenBank accession number KC013305) and 
DISCUSSION
In this study, we retrospectively studied suspected cases of dengue and found a large prevalence (63.2%) of B19V in patients' serum. Despite several seroprevalence studies [44] [45] [46] and some sporadic cases in the state of Rio de Janeiro [47, 48] , the public attention to B19V in Brazil is limited. To our knowledge, B19V is rarely tested for or even diagnosed in public health centers. Moreover, its febrile prodromal disease (ie, prerash and prearthritis symptoms) is often mistaken for more prevalent pathogens such as dengue. Dengue infections occur all year round in Brazil, but explosive outbreaks tend to happen during the summer months of November to April [22] [23] [24] . A high number of dengue cases lead to clinical diagnoses based on epidemiological grounds, which we showed here can lead to cryptic outbreaks of pathogens with similar disease outcomes. We found that during the 2013-2014 B19V outbreak in Guarujá, infections peaked in the late spring and early summer months of November through January (Figure 1 ), which agreed with other reports of erythema infectiosum outbreaks [37, 41, [49] [50] [51] , and occurred in a similar time frame of locally reported dengue outbreaks [22, 24] . Furthermore, clinical and hematological manifestations of B19V-infected patients were also found to be similar to classical dengue disease presentations such as fever, headache, myalgia, and retro-orbital pain [14] . This is especially true for the 8 patients who presented with retro-orbital pain-a symptom that has no known association with the B19V disease-and with thrombocytopenia, a common feature and diagnostic marker of dengue.
Today, qRT-PCR and quantitative ELISA are considered the gold standard for B19V diagnostics [32, 52] . Detection of B19V DNA in serum is circumstantial evidence for an infection, but cannot alone determine whether the viremia in question is acute or persistent because of its prolonged presence after infection [36, 53] . The lack of any IgM or IgG antibodies in 50 symptomatic cases could be a strong indication for a first-time infection, which is surprising since the majority of patients were adults and B19V exposure typically happens during childhood [54] . Moreover, we only detected IgM antibodies in 12 cases, which is much less than the number of PCR-positive cases. In these cases, it is possible that the majority of patients were attended very early in their illness and before their IgM antibody response could be detected [13, 21] .
We also found 47 symptomatic patients who were PCR and IgG positive, but IgM negative. We are aware of 4 explanations that could account for this: (i) an acute infection where the patient could not elicit an IgM response; (ii) a prolonged acute infection that lingered after the disappearance of IgM antibodies and was not completely neutralized by IgG [13] ; (iii) a persistent infection where a secondary viral reactivation or relapsing infection led to secondary clinical manifestations [28, 30, 31] ; and (iv) the presence of low levels of B19V DNA from a previous infection that have no correlation to the current clinical manifestations [36] . The majority of patients had viral loads indicative of a past infection, yet they were similar to the distribution of patients with who were considered acute by serology, PCR positive, and IgM and IgG negative. Surprisingly, 11 patients who were PCR and IgG positive had very high viral loads, indicative of a prolonged or reactivated infection (Table 2 ). Nevertheless, although we had evidence for persistent infections, there were roughly 20% of acute infections among the B19V cases we found, supporting a claim for an outbreak of B19V in Guarujá at that time. Even with viral loads and clinical records for some patients, we were uncertain how to determine which of the above-mentioned possibilities were most likely.
This outbreak served as an example that current passive surveillance measures could be vulnerable to missing a mild pathogen like B19V, which in turn also raises concerns that we could be overlooking more severe pathogens too. Here, we found high amounts of B19V in dengue-suspected patients where no diagnosis could be previously confirmed. Significantly, we found that despite a negative DENV diagnosis, 34% of patients with medical records were still clinically diagnosed with dengue (Table 1) . In one case, an official case notification for dengue without any diagnostic evidence was found on the patient's medical record. This further illustrates that even known viruses could circulate camouflaged underneath diagnostic detection. Although relatively expensive, we advocate for the situational use of next-generation sequencing for symptomatic but negatively diagnosed patients during large seasonal outbreaks of dengue or other febrile illnesses. Our findings provide an example that a medically important virus like B19V can be neglected by passive surveillance systems during a dengue outbreak. Crucially, it demands greater attention in surveillance systems to viruses showing similar clinical presentations.
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